All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
An expert panel hosted by
Customizing first-line BTK inhibitors for CLL
with Gilles Salles, Paolo Ghia, and Francesc Bosch
Wednesday, October 23, 2024
18:30-19:30 BST
This independent educational activity is supported by Pharmacyclics LLC, an AbbVie Company and Janssen Biotech. All content is developed independently by the faculty. The funder is allowed no influence on the content of this activity.
The Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Characteristics associated with response in patients with R/R CLL/SLL treated with liso-cel: TRANSCEND-CLL-004 post hoc analysis
|
The phase I/II TRANSCEND-CLL-004 trial (NCT03331198) assessed the safety and efficacy of liso-cel in adult patients with R/R CLL/SLL.1 The primary results from this trial were previously reported by the Lymphoma Hub. Briefly, the ORR and CR/CRi rates at DL2 were 47% and 18%, respectively. Based on results from this trial, liso-cel was approved by the FDA for the treatment of adult patients with R/R CLL/SLL who received ≥2 prior lines of therapy, including a BTKi and a BCL-2 inhibitor. A post hoc analysis of this trial assessed the correlations between patient characteristics and efficacy response and safety in patients treated at DL2 (n = 87). Results from this analysis were presented at the SOHO 2024 Annual Meeting by Wierda.1 |
| Key learnings: |
|
ORR and CRR were similar in patients with or without high-risk disease features at baseline, including unmutated IGHV (ORR, 41.5% vs 63.2%; CRR , 22.0% vs 21.1%), del(17p) (ORR, 47.1% vs 45.1%; CRR, 26.5% vs 13.7%), TP53 mutation (ORR, 41.7% vs 50.0%; CRR, 22.2% vs 16.0%), del(17p) and TP53 mutation (ORR, 44.0% vs 46.7%; CRR, 28.0% vs 15.0%), and complex karyotype (ORR, 44.2% vs 52.9%; CRR, 19.2% vs 17.6%). |
|
Patients with fewer prior lines of treatment and lower baseline tumor burden showed improved response rates; the ORRs for patients with ≤3 prior lines of therapy vs >3 prior lines of therapy were 54.5% vs 44.6%, and for patients without bulky (≥5 cm) disease vs with bulky disease were 63.2% vs 31.7%. |
|
Inflammatory markers, bulky disease, and lower estimated CrCl rates may be associated with a higher risk of neurological events. |
|
These findings highlight the benefit of liso-cel in patients with R/R CLL/SLL, regardless of high-risk disease features, and suggest that patients treated in earlier lines of therapy with a lower tumor burden may have improved outcomes. |
Abbreviations: BCL-2, B-cell lymphoma 2; BTKi, Bruton tyrosine kinase inhibitor; DL, dose level; FDA, U.S. Food and Drug Administration; IGHV, immunoglobulin heavy chain gene; CI, confidence interval; CLL, chronic lymphocytic leukemia; CrCl, creatinine clearance; CRi, CR with incomplete blood count recovery; CRR, complete response rate; liso-cel; lisocabtagene maraleucel; OR, odds ratio; ORR, overall response rate; R/R, relapsed/refractory; SLL, small lymphocytic lymphoma; SOHO, Society of Hematologic Oncology.
- Wierda WG. Characteristics associated with response to lisocabtagene maraleucel (liso-cel) in patients with R/R CLL/SLL: Exploratory analyses from the phase 1/2 TRANSCEND CLL 004 study. Oral Abstract #CLL-184. Presented at: Society of Hematologic Oncology 2024 Annual Meeting; Sep 4–7, 2024; Houston, US.
Understanding your specialty helps us to deliver the most relevant and engaging content.
Please spare a moment to share yours.
Please select or type your specialty
Thank youYour opinion matters
14 votes - 25 days left ...
Related articles
Newsletter
Subscribe to get the best content related to lymphoma & CLL delivered to your inbox